ScoreWhy is Novelix Pharmaceuticals Ltd ?
1
Poor Management Efficiency with a low ROE of 0.76%
- The company has been able to generate a Return on Equity (avg) of 0.76% signifying low profitability per unit of shareholders funds
2
Low ability to service debt as the company has a high Debt to EBITDA ratio of -1.00 times
- Low ability to service debt as the company has a high Debt to EBITDA ratio of -1.00 times
- The company has been able to generate a Return on Equity (avg) of 0.76% signifying low profitability per unit of shareholders funds
3
Healthy long term growth as Net Sales has grown by an annual rate of 153.19%
4
With a growth in Net Profit of 88.68%, the company declared Very Positive results in Dec 25
- The company has declared positive results for the last 3 consecutive quarters
- NET SALES(Q) Highest at Rs 48.40 cr
- PBDIT(Q) Highest at Rs 1.31 cr.
- OPERATING PROFIT TO NET SALES(Q) Highest at 2.71%
5
With ROE of 7.1, it has a Expensive valuation with a 4.5 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Novelix Pharma. should be less than 10%
- Overall Portfolio exposure to Retailing should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Retailing)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
171.26%
EBIT Growth (5y)
26.40%
EBIT to Interest (avg)
0.32
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.06
Sales to Capital Employed (avg)
1.18
Tax Ratio
16.78%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
-5.80%
ROE (avg)
1.22%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
54
Industry P/E
36
Price to Book Value
4.19
EV to EBIT
43.34
EV to EBITDA
41.83
EV to Capital Employed
4.41
EV to Sales
1.31
PEG Ratio
0.12
Dividend Yield
NA
ROCE (Latest)
2.76%
ROE (Latest)
7.79%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend20What is working for the Company
NET SALES(Latest six months)
At Rs 62.10 cr has Grown at 43.72%
PAT(Q)
Highest at Rs 1.18 cr.
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Novelix Pharma.
Net Sales - Latest six months
At Rs 62.10 cr has Grown at 43.72%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 1.18 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
